Work

Efficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): Subgroup analysis from the phase III JAVELIN renal 101 trial of first-line avelumab plus axitinib (A + Ax) vs sunitinib (S)

Year: 2019

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdz249.009

Authors: T.K. Choueiri, J.M.G. Larkin, S.K. Pal, R.J. Motzer, B. Venugopal, B.Y. Alekseev, H. Miyake, G. Gravis, M.A. Bilen, A. Chudnovsky, K.A. Ching, M. Mariani, P.B. Robbins, B. Huang, A. di Pietro, L. Albiges

Institutions: Brigham and Women's Hospital, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, Royal Marsden NHS Foundation Trust, Royal Marsden Hospital, City Of Hope National Medical Center, City of Hope, Memorial Sloan Kettering Cancer Center, Beatson West of Scotland Cancer Centre, University of Glasgow, P.A. Hertzen Moscow Oncology Research Institute, Hamamatsu University, Hamamatsu University School of Medicine, Institut Paoli-Calmettes

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2977671651

FWCI: 4.792

Cites:

Cited by: 35

Related to: 10